Introducing New Proficiency Tests – An Overview of the Prototype Proficiency Tests

Company
Proficiency Test
Year
AstraZeneca
BRCA/HRR Prostate carcinoma (tissue)
2020
AstraZeneca
BRCA 1/2 (Phase II) ovarian carcinoma
2017
AstraZeneca
T790M (Phase I) NSCLC
2016
AstraZeneca
T790M (Phase II) NSCLC
2017
Bayer
NTRK Genetic fusion
2019
Blueprint Medicines
GIST (Adaptation proficiency test)
2020
Bristol-Myers Squibb
PD-L1 malignant melanoma
2016
Bristol-Myers Squibb/Merck Sharp & Dohme
PD-L1 NSCLC (Phase II)
2017
Janssen Cilag
FGFR3 Urothelial carcinoma
2020
Lilly
EGFR IHC sqNSCLC
2016
Lilly
RET-Genetic fusion (ISH and NGS)
2021
Lilly
RET-Mutations
2021
Merck Sharp & Dohme
PD-L1 NSCLC (Phase I)
2016
Merck Sharp & Dohme
PD-L1 HNSCC
2020
Merck Sharp & Dohme
PD-L1 Urothelial carcinoma (Phase II)
2020
Merck Sharp & Dohme/ Roche
PD-L1 Urothelial carcinoma (Phase I)
2019
Merck Sharp & Dohme/ Roche
PD-L1 TNBC
2019
Novartis
BRAF V600 NSCLC
2017
Novartis
PIK3CA mamma carcinoma
2020
Pierre Fabre
BRAF V600E Colon carcinoma
2020
Pfizer
ROS1 NSCLC
2019
Roche
ALK NSCLC
2019

 

Status 08/2020

 

Icon

Contact form

Send us a message.

Please fill out this field.
Please enter valid email address.
Please choose from below
Please fill out this field.
You must agree before submitting.